Scarica l'app Stockscreener
82.24
3.10%
-2.63
Dopo l'orario di chiusura:
82.14
-0.10
-0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$84.87
Aprire:
$83.39
Volume 24 ore:
1.89M
Relative Volume:
0.75
Capitalizzazione di mercato:
$11.17B
Reddito:
$105.82M
Utile/perdita netta:
$-829.61M
Rapporto P/E:
-12.02
EPS:
-6.8429
Flusso di cassa netto:
$-548.92M
1 W Prestazione:
-3.89%
1M Prestazione:
+17.23%
6M Prestazione:
+29.86%
1 anno Prestazione:
+122.21%
Intervallo 1D:
$80.90
$84.60
Intervallo di 1 settimana:
$80.90
$87.93
Portata 52W:
$32.89
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
82.24 | 11.52B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Wells Fargo | Overweight |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-12-18 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Is Cytokinetics (CYTK) A Bargain On Myqorzo Approval Or Already Fully Priced? - Yahoo Finance
How Myqorzo’s Commercial Launch At Cytokinetics (CYTK) Has Changed Its Investment Story - Yahoo Finance
Price to sales forward of Cytokinetics, Incorporated – NASDAQ:CYTK - TradingView
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure? - Yahoo Finance
Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $108.47, Implies 26% Upside - TradingView
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
FMR LLC holds 5.25M shares of Cytokinetics (NASDAQ: CYTK) in 13G/A - Stock Titan
CYTOKINETICS (CYTK) EVP exercises options, sells 3,500 shares in open market - Stock Titan
CYTK (NASDAQ: CYTK) files Form 144 for 24,500-share option exercise sale - Stock Titan
Cytokinetics’ SWOT analysis: cardiovascular stock eyes growth with Myqorzo By Investing.com - Investing.com Nigeria
Cytokinetics’ SWOT analysis: cardiovascular stock eyes growth with Myqorzo - Investing.com
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Cuts Target Price to $117 - Moomoo
CYTK Maintained by RBC Capital -- Price Target Lowered to $117 - GuruFocus
RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating - marketscreener.com
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 - The Manila Times
Cytokinetics lands three ESC 2026 presentations on heart drug data - Stock Titan
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of ... - Caledonian Record
CYTKCytokinetics Inc Latest SEC Filings - Finviz
Cytokinetics CEO Robert Blum sells $636,900 in stock - Investing.com UK
Insider Sell Alert: EVP, Chief Financial Officer Sung Lee Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
CYTK News | CYTOKINETICS INC (NASDAQ:CYTK) - ChartMill
Cytokinetics EVP Andrew Callos sells $1.29 million in shares - Investing.com UK
Cytokinetics CEO Robert Blum sells $636,900 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $1.29 million in shares By Investing.com - Investing.com South Africa
Cytokinetics Insider Sold Shares Worth $1,287,000, According to a Recent SEC Filing - marketscreener.com
Cytokinetics (NASDAQ: CYTK) CEO trims stake with 7,500-share sale - Stock Titan
Cytokinetics (NASDAQ: CYTK) EVP exercises options, sells 15,000 shares at $85.80 - Stock Titan
CYTOKINETICS (NASDAQ: CYTK) CFO exercises options, sells 1,112 shares at $87.79 - Stock Titan
Form 144 CYTOKINETICS For: 1 July By Investing.com - Investing.com UK
CYTK insider Robert Blum notifies planned sale of 44,990 shares (CYTK) - Stock Titan
Cytokinetics Inc stock hits 52-week high at $88.00 - Investing.com
Cytokinetics Inc stock hits 52-week high at $88.00 By Investing.com - Investing.com India
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Cytokinetics (CYTK) - The Globe and Mail
Cytokinetics CFO Lee Sung sells $3.18m in company stock By Investing.com - Investing.com South Africa
Cytokinetics CFO Lee Sung sells $3.18m in company stock - Investing.com
Form 144 CYTOKINETICS For: 29 June By Investing.com - Investing.com South Africa
Form 4 Cytokinetics Inc For: 29 June By Investing.com - Investing.com South Africa
Cytokinetics(CYTK.US) Officer Sells US$3.19 Million in Common Stock - Moomoo
Cytokinetics (CYTK) CFO sells 38,730 shares at $82.30 after exercising options - Stock Titan
Cytokinetics CFO Lee Sung sells $266,390 of company stock By Investing.com - Investing.com South Africa
Cytokinetics CFO Lee Sung sells $266,390 of company stock - Investing.com
Cytokinetics (NASDAQ: CYTK) CFO trades shares after option exercises - Stock Titan
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cytokinetics Inc Azioni (CYTK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Jul 07 '26 |
Sale |
86.62 |
3,500 |
303,170 |
153,902 |
5.60%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):